Patients with primary or early-stage ER+/HER2- breast cancer generally have a favorable outlook, with excellent 5-year survival rates on endocrine therapy, even without the use of adjuvant chemotherapy (Early Breast Cancer Trialists' Collaborative et al., 2012). This evidence concerns the gene ERBB2 and breast carcinoma.